When patients receiving anti-viral treatment, it is critical that the viral load must be controlled to the lowest possible, be the patient is treatment-naïve, or treatment-experienced, be the patient HBeAg-positive or HBeAg-negative, be the patient in compensated or de-compensated stage.

The efficacy and safety data of Baraclude^®  on treatment in adefovir, lamivudine and telbivudine treatment-experienced HBeAg-positive or negative patients demonstrates that Baraclude^® is able to bring down the HBV virus regardless the patient background in a real life setting, and is an ideal agent in CHB long-term management.

The new Chinese treatment guideline emphasizes again that anti-viral treatment of the strongest viral suppression activity and of the lowest drug resistance rate over long-term treatment should be considered as the first-line treatment.

点击小图看大图